GlassScriptPhysician profile
Yong Liu
NPI 1316137987
$23,028.50
in general payments reported to CMS, 2019-2025
41 companies · $3,295 in 2025
The $3,295 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,954 · 2020: $2,397 · 2021: $3,750 · 2022: $4,065 · 2023: $3,843 · 2024: $3,725 · 2025: $3,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,862.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,210.45 | 2019-2024 | Xarelto |
| Janssen Biotech, INC. | $2,103.05 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $1,997.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,626.13 | 2020-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $1,559.30 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $1,486.40 | 2021-2025 | |
| Novo Nordisk INC | $1,454.22 | 2020-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $1,240.19 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $1,120.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,104.88 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Gilead Sciences, INC. | $986.56 | 2020-2025 | |
| Amarin Pharma, INC. | $695.71 | 2019-2021 | |
| Abbvie INC. | $655.51 | 2021-2025 | |
| Esperion Therapeutics, INC. | $561.81 | 2020-2025 | Nexletol |
| Radius Health, INC. | $549.83 | 2019-2025 | Tymlos |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.